{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:50Z","timestamp":1760184770169,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.hoc.2006.11.012","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T10:06:10Z","timestamp":1169719570000},"page":"51-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding"],"prefix":"10.1016","volume":"21","author":[{"given":"Linda","family":"Shore-Lesserson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2006.11.012_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell-based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2006.11.012_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0038-1642495","article-title":"Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro","volume":"71","author":"Michelson","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1537-2995.1970.tb00737.x","article-title":"Behavior of previously frozen erythrocytes used during open-heart surgery","volume":"10","author":"Valeri","year":"1970","journal-title":"Transfusion"},{"key":"10.1016\/j.hoc.2006.11.012_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00000542-199109000-00008","article-title":"Blood conservation techniques and platelet function in cardiac surgery","volume":"75","author":"Boldt","year":"1991","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hoc.2006.11.012_bib5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/00000542-199806000-00022","article-title":"In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression","volume":"88","author":"Faraday","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hoc.2006.11.012_bib6","first-page":"H528","article-title":"Effect of heparin on fibrinolytic activity and platelet function in vivo","volume":"271","author":"Upchurch","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0022-5223(19)34155-8","article-title":"Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage","volume":"105","author":"John","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hoc.2006.11.012_bib8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/00000542-199706000-00021","article-title":"The effects of heparinase 1 and protamine on platelet reactivity","volume":"86","author":"Ammar","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hoc.2006.11.012_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0049-3848(94)90174-0","article-title":"At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects","volume":"75","author":"Carr","year":"1994","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2006.11.012_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000542-199110000-00004","article-title":"Modulation of platelet surface adhesion receptors during cardiopulmonary bypass","volume":"75","author":"Rinder","year":"1991","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hoc.2006.11.012_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0003-4975(97)01348-9","article-title":"The platelet thrombin receptor and postoperative bleeding","volume":"65","author":"Ferraris","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.hoc.2006.11.012_bib12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0003-4975(01)02821-1","article-title":"The antithrombotic and antiinflammatory mechanisms of action of aprotinin","volume":"72","author":"Landis","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.hoc.2006.11.012_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1067\/mtc.2000.108531","article-title":"The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1","volume":"120","author":"Poullis","year":"2000","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hoc.2006.11.012_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V68.3.783.783","article-title":"Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor in an experimental animal model","volume":"68","author":"Coller","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2006.11.012_bib15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0735-1097(03)00945-8","article-title":"Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?","volume":"42","author":"Tcheng","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(03)00944-6","article-title":"Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)","volume":"42","author":"Chan","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","article-title":"Abciximab reduces mortality in diabetics following percutaneous coronary intervention","volume":"35","author":"Bhatt","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2006.11.012_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A","volume":"72","author":"Savi","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies","volume":"164","author":"Hirsh","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2006.11.012_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2006.11.012_bib24","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.11.012_bib25","first-page":"156","article-title":"ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention\u2014summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2006.11.012_bib26","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2006.11.012_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1055\/s-0037-1615238","article-title":"The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit","volume":"80","author":"Herbert","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0735-1097(02)01954-X","article-title":"The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting","volume":"40","author":"Hongo","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/hrt.2004.058396","article-title":"Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis","volume":"92","author":"Purkayastha","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.hoc.2006.11.012_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2004.02.019","article-title":"Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting","volume":"128","author":"Chen","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hoc.2006.11.012_bib31","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood.V79.9.2495.bloodjournal7992495","article-title":"Bleeding time revisited","volume":"79","author":"Rodgers","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2006.11.012_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2007-1002659","article-title":"Bleeding time tables. A tabular summary of pertinent literature","volume":"16","author":"Rodgers","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-1002660","article-title":"Supplementary bleeding time bibliography","volume":"16","author":"Rodgers","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.ATV.10.6.1032","article-title":"Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study","volume":"10","author":"Elwood","year":"1990","journal-title":"Arteriosclerosis"},{"issue":"Suppl 4","key":"10.1016\/j.hoc.2006.11.012_bib35","first-page":"1","article-title":"The thromboelastography and the thromboelastograph technique","volume":"21","author":"Chandler","year":"1995","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2006.11.012_bib36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.V641250","article-title":"Thromboelastography for the prediction of bleeding after transplant renal biopsy","volume":"6","author":"Davis","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hoc.2006.11.012_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0022-2143(97)90040-8","article-title":"Monitoring platelet glycoprotein IIb\/IIIa-fibrin interaction with tissue factor-activated thromboelastography","volume":"130","author":"Khurana","year":"1997","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.hoc.2006.11.012_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.amjcard.2003.10.042","article-title":"Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization","volume":"93","author":"Mobley","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hoc.2006.11.012_bib39","first-page":"A-268","article-title":"Clopidogrel induces a platelet aggregation defect that is partially mitigated by ex-vivo addition of aprotinin","volume":"101","author":"Shore-Lesserson","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hoc.2006.11.012_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/0953710412331272532","article-title":"Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention","volume":"15","author":"Smith","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.hoc.2006.11.012_bib41","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2006.11.012_bib42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1365-2141.1999.01660.x","article-title":"Standardization of the PFA-100(R) platelet function test in 105 mmol\/l buffered citrate: effect of gender, smoking, and oral contraceptives","volume":"106","author":"Bock","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2006.11.012_bib43","first-page":"614","article-title":"Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation","volume":"84","author":"Escolar","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2006.11.012_bib44","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ahj.2005.01.015","article-title":"Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study","volume":"150","author":"Campbell","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hoc.2006.11.012_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1051\/ject\/1998304171","article-title":"Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer","volume":"30","author":"Carville","year":"1998","journal-title":"J Extra Corpor Technol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858806001973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858806001973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:49:39Z","timestamp":1760183379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858806001973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0889858806001973"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2006.11.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2006.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}